Berns becomes chairman, CEO of Neumora
Plus: Robin Kenselaar named chief commercial officer at Orchard, and an update from Bluejay
Paul Berns has become chairman and CEO of neuroscience company Neumora Therapeutics Inc. (NASDAQ:NMRA). Berns, who co-founded Neumora and was its executive chair, succeeds Henry Gosebruch, who had joined as president and CEO in 2023. Three other Neumora executives also got new roles. Joshua Pinto was named president, and his former role of CFO went to Michael Milligan, formerly SVP Finance. Bill Aurora, who was chief strategy officer, has become chief operating and development officer. The changes follow a disappointing data readout last month.
Orchard Therapeutics plc named Robin Kenselaar chief commercial officer. Kenselaar, who joined Orchard in 2018, was SVP and general manager of EMEA. Orchard, a Kyowa Kirin Co. Ltd. (Tokyo:4151) company developing hematopoietic stem cell-based gene therapies, also announced that it had reached a reimbursement agreement with Spain’s national health system for Lenmeldy atidarsagene autotemcel to treat metachromatic leukodystrophy...